CNTRL

Across TCGA pan-cancer cohorts, CNTRL mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated CNTRL data layer compared with 28 for mass-spec protein and 12 for mutation status.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher CNTRL mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated CNTRL expression acts as an unfavorable survival marker, although some lineages such as LUAD and PDAC show a favorable association.

LUAD, PDAC, and CCRCC are the cancer types where CNTRL mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	DFS	Median	All	0.761	0.500	.002	16	view →
PDAC	DFS	Median	III,IV	0.567	0.145	.003	16	view →
CCRCC	DFS	Quartile	III,IV	0.863	0.258	.017	12	view →
GBM	OS	Median	All	0.575	0.267	.011	6	view →
HNSC	DFS	Tertile	III,IV	1.000	0.623	.040	2	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

CNTRL–LUAD (DFS)

Open the LUAD breakdown →